STOCK TITAN

Insider Notice: Nu Skin filer plans to sell 20,000 Class A shares on NYSE

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Nu Skin Enterprises (NUS) filing a Form 144 notifies the SEC of a proposed sale of 20,000 Class A shares through Fidelity Brokerage Services on the NYSE, with an aggregate market value of $239,433.56 and approximately 49,497,715 Class A shares outstanding. The securities listed were acquired as restricted stock vesting from the issuer on multiple dates between 02/15/2022 and 02/15/2024, with individual lot sizes shown. The filer reports no securities sold in the past three months and affirms they possess no undisclosed material adverse information about the issuer. The notice includes required signature and legal attestation language.

Positive

  • Transparent compliance: The filer provided required Form 144 details including broker, share count, aggregate value, and acquisition history.
  • No recent sales: The filer reports "Nothing to Report" for securities sold in the past three months, reducing ambiguity about recent insider selling.

Negative

  • Insider sale proposed: The notice indicates a proposed sale of 20,000 Class A shares, which could be perceived negatively by some investors despite its small size relative to outstanding shares.

Insights

TL;DR Proposed sale is small relative to outstanding shares and stems from routine vested compensation.

The Form 144 shows a proposed transaction of 20,000 Class A shares valued at $239,433.56 to be executed through Fidelity on the NYSE. All reported lots were acquired via restricted stock vesting as compensation across 2022–2024, indicating these shares originated from granted awards rather than open-market purchases. No sales in the past three months are reported, which reduces near-term liquidity signal noise. The filing represents compliance with required insider sale notification rules but does not by itself indicate material corporate change.

TL;DR Filing is a routine insider-sale notice with standard attestations; impact appears neutral.

The disclosure meets Rule 144 notice requirements and includes the filer’s representation about lack of undisclosed material adverse information. The acquisition history details multiple vested restricted stock events, showing the shares are compensatory in nature. Absent other disclosures (e.g., a trading plan date or concurrent material events), this Form 144 is a routine governance compliance document rather than an indicator of governance concerns.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does Nu Skin (NUS) Form 144 disclose?

It discloses a proposed sale of 20,000 Class A shares via Fidelity on the NYSE with an aggregate market value of $239,433.56.

How were the shares being sold by the NUS filer acquired?

All listed shares were acquired through restricted stock vesting from the issuer on various dates between 02/15/2022 and 02/15/2024 as compensation.

Does the filing report recent insider sales for NUS?

No. The filing indicates "Nothing to Report" for securities sold during the past three months.

What broker and exchange will handle the proposed sale?

The broker is Fidelity Brokerage Services LLC and the sale is to occur on the NYSE.

What percentage of outstanding shares does the proposed sale represent?

The proposed 20,000 shares represent approximately 0.04% of the reported 49,497,715 Class A shares outstanding.
Nu Skin Enter

NYSE:NUS

NUS Rankings

NUS Latest News

NUS Latest SEC Filings

NUS Stock Data

489.94M
46.43M
2.16%
74.97%
3.89%
Household & Personal Products
Wholesale-drugs, Proprietaries & Druggists' Sundries
Link
United States
PROVO